公开(公告)号：US20240180898A1

公开(公告)日：2024-06-06

申请号：US18430780

申请日：2024-02-02

申请人： INNAMUNE PHARMACEUTICAL CO. LTD.

发明人： PING ZHOU ,  FENGCHAO JIANG

IPC分类号： A61K31/496 ,  A61K9/06 ,  A61P1/16 ,  A61P3/04 ,  A61P17/02 ,  A61P17/06 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P37/08

CPC分类号： A61K31/496 ,  A61K9/06 ,  A61P1/16 ,  A61P3/04 ,  A61P17/02 ,  A61P17/06 ,  A61P25/24 ,  A61P25/28 ,  A61P27/02 ,  A61P37/08

摘要： The invention provides a use of aminothiazole derivative in treatment of immune inflammation, the aminothiazole derivative can treat surface immune inflammatory dermatitis and immune surface inflammation, such as psoriasis, neurodermatitis, specific dermatitis eczema, atopic dermatitis, urticaria, seborrheic dermatitis and alopecia, abnormal scar, pathological pigmentation, etc. There are also immune inflammation caused by chronic rhinitis, conjunctivitis, dry eye, allergic asthma, chronic bronchitis, mucosal and epidermal injuries; It also includes chronic refractory immune inflammatory diseases such as various autoimmune diseases such as diabetes, systemic lupus erythematosus, rheumatoid disease; Metabolic inflammatory diseases such as obesity, fatty liver, metabolic inflammatory syndrome; Inflammatory cancer such as chronic colitis colon cancer, chronic hepatitis cirrhosis liver cancer; Ischemia-reperfusion injury, graft rejection and graft-versus-host disease, chronic inflammation of the nervous system such as neurodegeneration, Alzheimer's syndrome, depression, etc., have obvious effects, safety and non-toxic.

公开(公告)号：US20240166611A1

公开(公告)日：2024-05-23

申请号：US18395388

申请日：2023-12-22

申请人： GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR

发明人： Jin-Mo KU ,  Jin-Kyung IN ,  Jung-Hun LEE ,  Han-Na CHA

IPC分类号： C07D249/06 ,  A61P3/04

CPC分类号： C07D249/06 ,  A61P3/04

摘要： The present invention relates to a novel triazole derivative or a salt thereof. The triazole derivative or the salt thereof according to the present invention induces or promotes browning of white adipocytes, and differentiates stem cells, embryonic cells, or preadipocytes to brown adipocytes or beige adipocytes. A composition comprising the triazole derivative or the salt thereof according to the present invention can treat, prevent, or alleviate obesity, obesity complications, diabetes, dyslipidemia, fatty liver, hypertension, metabolic syndrome, and insulin resistance syndrome.

公开(公告)号：US11981695B2

公开(公告)日：2024-05-14

申请号：US17059361

申请日：2019-05-27

申请人： UNIVERSITÉ DE BOURGOGNE ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

发明人： Naim Khan ,  Sylvain Juge ,  Aziz Hichami ,  Jérôme Bayardon ,  Marie-Laure Louillat-Habermeyer ,  Baptiste Rugeri

IPC分类号： A23K20/158 ,  A23L33/00 ,  A23L33/12 ,  A61P3/04 ,  C07C233/47 ,  C07D263/16 ,  C07D303/16 ,  C07D305/06 ,  C07D307/12 ,  C07D319/06 ,  C07F9/40

CPC分类号： C07F9/4015 ,  A23K20/158 ,  A23L33/12 ,  A23L33/40 ,  A61P3/04 ,  C07C233/47 ,  C07D263/16 ,  C07D303/16 ,  C07D305/06 ,  C07D307/12 ,  C07D319/06 ,  A23V2002/00

摘要： Disclosed is a linoleic acid derivative of Formula (I) below including a hydrophobic part C17H31 linked to a polar head part “A”:






wherein the polar head part A is selected from A1 to A4 below:










or a pharmaceutically/food quality acceptable salt thereof.

公开(公告)号：US20240148884A1

公开(公告)日：2024-05-09

申请号：US18366653

申请日：2023-08-07

申请人： The Scripps Research Institute

发明人： Weijun SHEN ,  Zaid AMSO ,  Peter G. Schultz

IPC分类号： A61K47/64 ,  A61K47/54 ,  A61K47/59 ,  A61P3/04 ,  A61P3/10

CPC分类号： A61K47/64 ,  A61K47/542 ,  A61K47/595 ,  A61P3/04 ,  A61P3/10

摘要： Provided herein are peptides and peptide conjugates comprising a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The peptides may be used for blood glucose management and treating conditions such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US20240148879A1

公开(公告)日：2024-05-09

申请号：US18547160

申请日：2022-02-21

申请人： Spitfire Pharma LLC

发明人： M. Scot Roberts ,  Bertrand Victor Gilbert Georges

IPC分类号： A61K47/54 ,  A61K9/00 ,  A61K38/00 ,  A61P3/04 ,  C07K14/605

CPC分类号： A61K47/549 ,  A61K9/0019 ,  A61P3/04 ,  C07K14/605 ,  A61K38/00

摘要： This disclosure relates to the field of peptides, formulations, and methods of using the same, including but not limited to modified peptides derived from any of SEQ ID NOS. 1-29.

公开(公告)号：US11976040B2

公开(公告)日：2024-05-07

申请号：US18178062

申请日：2023-03-03

申请人： Mayo Foundation for Medical Education and Research

发明人： Vijay P. Singh ,  Sampath-Kumar Anandan ,  Kevin Greenman ,  Zeeshan Kamal

IPC分类号： A61K31/365 ,  A61P3/04 ,  C07D205/08

CPC分类号： C07D205/08 ,  A61K31/365 ,  A61P3/04

摘要： Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein:




or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240139262A1

公开(公告)日：2024-05-02

申请号：US18486674

申请日：2023-10-13

申请人： GRAPE KING BIO LTD

发明人： Chin-Chu CHEN ,  Yen-Lien CHEN ,  Shih-Wei LIN ,  Yen-Po CHEN ,  Ci-Sian WANG ,  Yu-Hsin HOU ,  Yang-Tzu SHIH ,  Ching-Wen LIN ,  Ya-Jyun CHEN ,  Jia-Lin JIANG ,  You-Shan TSAI ,  Zi-He WU

IPC分类号： A61K35/747 ,  A61K35/745 ,  A61P3/04 ,  A61P3/08 ,  A61P43/00

CPC分类号： A61K35/747 ,  A61K35/745 ,  A61P3/04 ,  A61P3/08 ,  A61P43/00 ,  C12R2001/225

摘要： The present disclosure relates to a complex probiotic composition and a method for improving exercise performance of a subject with low intrinsic aerobic exercise capacity. The complex probiotic composition, which includes Lactobacillus rhamnosus GKLC1, Bifidobacterium lactis GKK24 and Clostridium butyricum GKB7, administered to the subject with the low intrinsic aerobic exercise capacity in a continuation period, can effectively reduce serum lactic acid and serum urea nitrogen after aerobic exercise, reduce proportion of offal fat and/or increase liver and muscle glycogen contents, thereby being as an effective ingredient for preparation of various compositions.

公开(公告)号：US20240124541A1

公开(公告)日：2024-04-18

申请号：US18286453

申请日：2022-04-12

申请人： University of Florida Research Foundation, Incorprated

发明人： David Hammers ,  Hugh Lee Sweeney

IPC分类号： C07K14/495 ,  A61P3/04 ,  C07K14/47 ,  C12N15/86

CPC分类号： C07K14/495 ,  A61P3/04 ,  C07K14/4716 ,  C12N15/86 ,  C07K2319/01 ,  C12N2750/14143

摘要： The disclosure provides methods of treating obesity, reducing weight, or preventing weight gain using a combination therapy of GDF15 polypeptide and a myostatin inhibitor (e.g., a myostatin propeptide).

公开(公告)号：US20240122999A1

公开(公告)日：2024-04-18

申请号：US18278251

申请日：2022-02-14

申请人： Tate & Lyle Solutions USA LLC ,  University College Cork - National University of Ireland, Cork ,  Agriculture and Food Development Authority (TEAGASC)

发明人： Noel Caplice ,  Catherine Stanton ,  Paul Ross ,  Florence Herisson ,  Kavita Karnik ,  Mervyn De Souza ,  Ieva Laurie ,  Kirstie Canene-Adams

IPC分类号： A61K35/747 ,  A61K47/36 ,  A61P1/16 ,  A61P3/04 ,  A61P9/00

CPC分类号： A61K35/747 ,  A61K47/36 ,  A61P1/16 ,  A61P3/04 ,  A61P9/00 ,  A61K2035/115

摘要： The present disclosure provides compositions comprising Lactobacillus mucosae and soluble dietary fiber, and methods treatment related thereto, useful against metabolic syndrome and related diseases, disorders and morbidities.

公开(公告)号：US11957704B2

公开(公告)日：2024-04-16

申请号：US17823586

申请日：2022-08-31

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Luca Andrea Lotta ,  Parsa Akbari ,  Olukayode Sosina ,  Manuel Allen Revez Ferreira ,  Aris Baras

IPC分类号： A61K31/7105 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/46 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10

CPC分类号： A61K31/7105 ,  A61K31/7088 ,  A61K31/713 ,  A61K38/465 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10 ,  A61P9/10

摘要： The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.